The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 1×
“Cytochrome P450 1A2 (CYP1A2) accounts for about 15% of the total P450 content in the liver [1] and metabolises several important clinical drugs, such as clozapine [2], verapamil [3] and endogenous substrates such as melatonin [4] and estradiol [5].”
BackgroundSachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Coffee, CYP1A2 genotype, and risk of myocardial infarction
Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., & Campos, H. (2006) · JAMA · doi:10.1001/jama.295.10.1135 · Cited by 490 · cited 1×
“Despite the fact that CYP1A2*1F is argued to have an effect on enzyme inducibility, a recent study reported an association between coffee intake and an increased risk of nonfatal myocardial infarction among individuals carrying the CYP1A2*1F allele, who are defined as slow metabolisers, in both smokers and non-smokers…”
BackgroundNakajima, M., Yokoi, T., Mizutani, M., Kinoshitah, M., Funayama, M., & Kamataki, T. (1999) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022352 · Cited by 346
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
Bertilsson, L., Carrillo, J., Dahl, M.-L., LLerena, A., Alm, C., Bondesson, U., Lindström, L., de la Rubia, I. R., Ramos, S., & Benítez, J. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04385.x · Cited by 307
Self-citationRasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241 · cited 1×
“A study on monozygotic and dizygotic twins revealed that variations in CYP1A2 activity are mainly governed by genetic factors although environmental factors also play a role [8].”
BackgroundCaffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking
Kalow, W., & Tang, B.-K. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.8 · Cited by 213
Identification of P450 enzymes involved in metabolism of verapamil in humans
Kroemer, H., Gautier, J.-C., Beaune, P., Henderson, C., Roland Wolf, C., & Eichelbaum, M. (1993) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00169164 · Cited by 200
Impairment of Caffeine Clearance by Chronic Use of Low-Dose Oestrogen-Containing Oral Contraceptives
Abernethy, D. R., & Todd, E. L. (1985) · European Journal of Clinical Pharmacology · doi:10.1007/bf00544361 · Cited by 195
Yamazaki, H., Shaw, P. M., Guengerich, F. P., & Shimada, T. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970217f · Cited by 182
Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., & Ingelman-Sundberg, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.659 · Cited by 181
Self-citationThe karolinska cocktail for phenotyping of five human cytochrome P450 enzymes
Christensen, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00050-x · Cited by 157
Self-citationCarrillo, J. A., Christensen, M., Ramos, S., Alm, C., Dahl, M., Benítez, J., & Bertilsson, L. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200008000-00008 · Cited by 136
Self-citationChida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J., & Kamataki, T. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00832.x · Cited by 118
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype
Jiang, Z., Dragin, N., Jorge-Nebert, L. F., Martin, M. V., Guengerich, F. P., Aklillu, E., Ingelman‐Sundberg, M., Hammons, G., Lyn‐Cook, B. D., Kadlubar, F. F., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000204994.99429.46 · Cited by 93
Self-citationMurayama, N., Soyama, A., Saito, Y., Nakajima, Y., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kimura, H., Goto, Y., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055798 · Cited by 86
Kall, M., & Clausen, J. (1995) · Human & Experimental Toxicology · doi:10.1177/096032719501401004 · Cited by 69
Identification of a novel splice‐site mutation in the CYP1A2 gene
Allorge, D., Chevalier, D., Lo‐Guidice, J., Cauffiez, C., Suard, F., Baumann, P., Eap, C. B., & Broly, F. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01858.x · Cited by 65
Chevalier, D., Cauffiez, C., Allorge, D., et al. (2001) · Human Mutation · doi:10.1002/humu.49 · Cited by 64
The G−113A polymorphism in affects the caffeine metabolic ratio in a Chinese population
Chen, X., WANG, L., ZHI, L., Zhou, G.-D., WANG, H., ZHANG, X., Hao, B., Zhu, Y., Cheng, Z., & HE, F. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.012 · Cited by 63
The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women
Nordmark, A., Lundgren, S., Ask, B., Granath, F. N., & Rane, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01673.x · Cited by 60
Härtter, S., Ursing, C., Morita, S., Tybring, G., von Bahr, C., Christensen, M., Röjdmark, S., & Bertilsson, L. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116512 · Cited by 57
Self-citationPhenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy
Takata, K., Saruwatari, J., Nakada, N., Nakagawa, M., Fukuda, K., Tanaka, F., Takenaka, S., 修一, 三., Marubayashi, T., & Nakagawa, K. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0057-z · Cited by 41
Shimoda, K., Someya, T., Morita, S., Hirokane, G., Yokono, A., Takahashi, S., & Okawa, M. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00263-9 · Cited by 40
Todesco, L., T�r�k, M., hl, S. K. H., & Wenk, M. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0623-1 · Cited by 28
Larsen, J. T., & Brøsen, K. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_97365.x · Cited by 25
Coffee, Myocardial Infarction, and CYP Nomenclature
Ingelman‐Sundberg, M., Sim, S. C., & Nebert, D. W. (2006) · JAMA · doi:10.1001/jama.296.7.764-b · Cited by 10
Self-citation
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Evidence for epigenetic regulation of CYP1A2 expression was shown by measuring the extent of DNA methylation of a CpG island close to the translation start site, which was inversely correlated to hepatic CYP1A2 mRNA levels (Ghotbi et al., 2007; Dobrinas et al., 2011).”
BackgroundResultInfluentialIngelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Self-citationPolymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
International society of sports nutrition position stand: caffeine and performance
Goldstein, E. R., Ziegenfuss, T., Kalman, D., Kreider, R., Campbell, B., Wilborn, C., Taylor, L., Willoughby, D., Stout, J., Graves, B. S., et al. (2010) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-7-5 · Cited by 686
International Society of Sports Nutrition Position Stand: Caffeine and Exercise Performance
Guest, N. S., VanDusseldorp, T. A., Nelson, M. T., Grgic, J., Schoenfeld, B. J., Jenkins, N. D. M., Arent, S. M., Antonio, J., Stout, J. R., Trexler, E. T., et al. (2021) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-020-00383-4 · Cited by 665
Metadata
- Authors
- Ghotbi, R., Christensen, M., Roh, H.-K., Ingelman-Sundberg, M., Aklillu, E., & Bertilsson, L.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2007-03-17
- Volume
- 63
- Issue
- 6
- Pages
- 537-546
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2049033995
- Cited by
- 264
- References
- 27
- FWCI
- 13.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.